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Chagas disease is caused by the parasite Trypanosoma cruzi, and is
a serious public health concern in Latin America. Chagasic chronic
cardiomyopathy (CCC) is the most signiﬁcant clinical manifestation of
the disease, due to its potential severity. CCC is characterized by
extreme clinical variability, making the prediction of the progress of
cardiac dysfunction a challenge for many researchers [1,2].
Brain Derived Neurotrophic Factor (BDNF) is a neurotrophin ﬁrst
recognized by its action on neuronal targets [3]. Growing evidence has
implicated BDNF in several nonneuronal phenomena, and circulating
levels of the factor have been proposed as a peripheral marker for a
variety of disorders, including those pertaining to the cardiovascular
system [4–6].
We assessed BDNF serum levels in chronic chagasic patients in
order to correlate with the degree of cardiac dysfunction. Patients
were recruited from an outpatient reference center for Chagas Disease
treatment (Centro de Tratamento e Referência emDoenças Infecciosas
e Parasitárias, in Belo Horizonte, MG, Brazil). Informed consent was
obtained from all subjects. The protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki as reﬂected in a priori
approval by our institutional human ethics committee, protocol
number 001/97.
Healthy subjects formed the control group (C) which was com-
prised of 18 men and 8 women, aged 22–55 years (mean±SD=
36.5±9.4 years). Chagasic patients where divided into 3 groups:
asymptomatic (A), non-dilated cardiopathic (ND), and dilated cardio-
pathic (D). These 3 groups were segregated based on ventricular
dysfunction and conduction defects, assessed by electrocardiogram
(ECG) and echocardiogram tests. Group A was comprised of asympto-
matic patients whose ECG showed no alteration or discrete or minor
alterations. None of the patients in this group had conduction defects.
Patients in group ND had considerable ECG alterations and were
characterized by advanced conduction defects and/or severe arrhyth-
mia, but with no ventricular enlargement. Group D included patients
with signs of heart enlargement and global systolic dysfunction. The
principal clinical characteristics of the chagasic patients are depicted in
Table 1.
BDNF serum levels were determined by ELISA (Enzyme Linked
Immuno Sorbent Assay), using kit and protocol from R&D Systems
(Minneapolis, MN, USA). Nonparametric Mann–Whitney and Spearman
Rank correlation tests were performed, with signiﬁcance levels at 0.001%
and 0.05%.
Serum levels of BDNF were signiﬁcantly higher in all groups of
chagasic patients when compared to those in the control group
(median [interquartile range]; 597.6 [249.9–5964] pg/mL). Groups A
and ND presented similar BDNF levels (5353 [2003–7054] pg/mL and
5782 [3163–7995] pg/mL, respectively). In contrast, Group D
presented lower BDNF levels (3584 [1205–7309] pg/mL) than those
of groups A and ND (Fig. 1a). The Spearman Rank test showed a
positive correlation between BDNF levels and ejection fraction
(r=0.3137, p=0.0431), and a negative correlation between BDNF
levels and ventricular dilatation index (r=−0.3146, p=0.0424) in
chagasic patients (Fig. 1b and c).
A role for BDNF has been established in themodulation of the heart
autonomic nervous system [5,7]. Chagasic patients, even the asymp-
tomatic ones, are considered to have dysautonomia which does not
always manifest as an alteration of heart rate and atrioventricular
conduction [8,9]. Thus, autonomic denervation could account for, at
least partially, the high levels of BDNF observed in chagasic patients.
Denervated cardiomyocytes could be among the cells contributing to
the elevation of BDNF levels, since it is known that these cells secrete
neurotrophic factors, including BDNF [10,11]. In some conditions of
autonomic denervation, including T. cruzi infection, cardiomyocytes
are stimulated to secrete neurotrophic factors, as demonstrated for
Nerve Growth Factor and Glial Derived Neurotrophic Factor [12–14]. It
is important to consider that in chagasic patients with severe
cardiomyopathy there is an appreciated ﬁbrosis [8,15]. This could
result in a decrease in the number of cardiomyocytes available for
BDNF synthesis, and explain, at least partially, the lower serum levels
of BDNF in patients with dilated cardiomyopathy. Inﬂammatory cells
could be another important source of BDNF in chagasic patients, as
these cells are considered a major source of BDNF and this
neurotrophin production is increased upon antigen stimulation [16].
Finally, we cannot discard other possible sources of circulating BDNF
such as vascular smooth muscle cells which can secrete BDNF [5].
Vasculopathy is well established as another phenomenon associated
to CCC [17], and T. cruzi infection results in smooth muscle cell
activation and proliferation [18]. Thus, these cells could contribute to
the BDNF levels found in the blood of chagasic patients.
Table 1
Clinical data from control (healthy) and chagasic patients.
Group C Group A Group ND Group D
Number of patients 26 11 15 29
Age
Mean±SD 36.5±9.4 41.1±7.5 50.7±10.3 50.8±10.3
Range 22–55 28–52 27–60 36–70
Male/female 18/08 10/01 09/06 21/08
Ejection fraction (%)
Mean±SD – 64.5±6.5 59.3±8.6⁎ 41.6±9.5⁎⁎
Range 49–70 35–67 18–56
Left Ventricular Dilatation
Index (mm)
Mean±SD – 50.0±5.2 53.3±4.7 62.4+4.9⁎⁎
Range 42–61 35–67 54–74
C = control subjects; A = asymptomatic chagasic patients; ND = non-dilated
cardiopathic chagasic patients; D = dilated cardiopathic chagasic patients.
⁎ pb0.05.
⁎⁎ pb0.0001.
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In conclusion elevated levels of serum BDNF are associated with
Chagas disease. More, there is a signiﬁcant correlation between serum
BDNF levels and two clinical variables routinely used to evaluate cardiac
function, ventricle enlargement and low ejection fraction. The under-
lyingmechanism as to how remains unclear, but a relationship between
BDNF serum levels and both cardiac autonomic denervation and
inﬂammatory processes is supported. Although not directly associated
to the severity of disease, serum BDNF levels could, to some degree,
predict the evolution of patients to the dilated form of the disease. To
conﬁrm this, a longitudinal study involving a greater number of chagasic
patients in varying stages of the disease is necessary.
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Fig. 1. a. BDNF levels in healthy controls and in chagasic patients. C = control patients;
A= asymptomatic chagasic patients; ND=non-dilated cardiopathic chagasic patients;
D = dilated cardiopathic chagasic patients. * pb0.001 vs group C. # pb0.05 vs groups A
and ND. b. Correlation between serum BDNF levels and ejection fraction in chagasic
patients. r=0.3137, pb0.05. c. Correlation between serum BDNF levels and ventricular
dilatation index in chagasic patients. r=−0.3146, pb0.05.
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